Account
Articles
03.11.2025
Designing Payer-Ready Trials in 2025: Five Decisio...

Clinical innovation has never moved faster. Tools like single-arm designs, novel surrogates, and ada...

Read more
Poster
15.10.2025
What Are the Likely PICOs for Tovorafenib and Lifi...

Objectives:  ​​EUHTA regulation has applied from the 1st January 2025 for oncology pr...

Read more
Poster
15.10.2025
How the EU JCA could interface with Regional Prici...

Objectives: ​​To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...

Read more
Articles
13.10.2025
Surrogates Under Scrutiny: Proving the Link to Out...

Surrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...

Read more
Articles
08.10.2025
Orchestrating Evidence Needs: Overcoming Regulator...

Optimising evidence generation in trial design, while navigating regulatory and local payer requirem...

Read more
Guide
08.09.2025
The BRAVE Approach: Your Guide to Early Payer Scie...

Successfully navigating early payer scientific advice whether through Joint Scientific Consultations...

Read more
Articles
08.09.2025
The JCA is here – are you generating the right e...

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu...

Read more
Articles
20.08.2025
Reassessing Clinically Meaningful Differences in A...

The recent Medicines and Healthcare products Regulatory Agency (MHRA) approval of the Alzheimer’s ...

Read more
Articles
11.08.2025
Why your PICO strategy matters to successful JCA 

The Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...

Read more
Articles
14.07.2025
Engaging Stakeholders: The Power of Patient and Cl...

Decisions regarding National Institute for Health and Care Excellence (NICE) appraisals are not made...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.